If you’re starting a biotechnology company and thinking of developing anything other than a super-high-priced medicine for a niche market, this morning’s news that Questcor Pharmaceuticals is being bought by Dublin-based specialty pharma Mallinckrodt for $5.6 billion may make you reconsider. Forget new drugs for any common diseases, find an old one that you can justify charging a lot more for.